Permit an opioid treatment program to be developed if part of a clinical trial, approved by an institutional review board
Impact
If enacted, HB228 will significantly impact the state's approach to substance abuse treatment by legitimizing opioid treatment programs that are integrated with clinical research. This means that facilities engaging in these treatments must have a defined approval process, including registering with the Board of Pharmacy and adhering to specific guidelines prescribed by the law. By allowing advanced practice registered nurses (APRNs) engaged in clinical trials to dispense medications without the standard prescription limitations, the bill seeks to enhance medication-assisted treatment options, particularly for those suffering from opioid use disorder.
Summary
House Bill 228 aims to amend several provisions related to the development and approval of opioid treatment programs within West Virginia. Specifically, the bill allows for the establishment of such programs only if they are part of an approved clinical trial that has received institutional review board (IRB) approval. This legislative initiative is intended to regulate the conditions under which opioid treatment programs can operate, ensuring that they comply with state mandates and safeguard patient welfare through oversight and structured research protocols.
Sentiment
The general sentiment around HB228 appears mixed, with support from those who prioritize regulatory oversight in opioid treatment to ensure the efficacy and safety of new approaches. Supporters argue that establishing clear frameworks for opioid treatment programs through clinical research could provide much-needed data to combat the opioid crisis. Conversely, there may be concerns from certain stakeholders who fear that introducing such frameworks might slow down the immediate availability of treatments, potentially leaving patients without timely access to necessary therapies during the trial periods.
Contention
Notable points of contention regarding HB228 include the trade-offs between strict regulation and the urgency to provide timely treatment options for individuals with opioid addiction. Critics may argue that while the intention of the bill is to ensure quality and safety, the requirement for clinical trials and IRB approval could inadvertently delay treatment for those in critical need. Additionally, there may be debates about the extent to which APRNs should be empowered to dispense medications without conventional restrictions, raising questions about training and accountability in the context of public health.
Making a supplementary appropriation to the Department of Human Services, Bureau for Medical Services – Policy and Programming and State Board of Education – State Department of Education
Regulation of pharmacy benefit managers, fiduciary and disclosure requirements on pharmacy benefit managers, and application of prescription drug payments to health insurance cost-sharing requirements. (FE)